



ITW

PATENT  
1503-1083

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Mallen HUANG

Conf. 6727

Application No. 10/551,804

Group 1636

Filed August 3, 2006

Examiner unknown

NUCLEOTIDE VACCINE COMPOSITION

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with Rules 1.97 and 1.98, and in fulfillment of the duty of disclosure under Rule 1.56, the accompanying documents, copies of which are attached to this statement, are made of record on the enclosed Form PTO-1449.

A concise explanation of the relevance of these items is that these references were cited by the European and Chinese Patent Offices in the corresponding European and Chinese Applications.

Under the provisions of 37 CFR 1.97(e), the undersigned hereby certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

YOUNG & THOMPSON

A handwritten signature in black ink, appearing to read 'Robert J. Patch', written over a horizontal line.

Robert J. Patch, Reg. No. 17,355  
745 South 23<sup>rd</sup> Street  
Arlington, VA 22202  
Telephone (703) 521-2297  
Telefax (703) 685-0573  
(703) 979-4709

RJP/blg

September 7, 2007

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

 Attorney Docket No.:  
**1503-1083**

Application No.:

 Applicant:  
**Mallen HUANG**

 Filing Date:  
**August 3, 2006**

Group Art Unit:

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 00/15264	3/23/2000	WO			*	
	WO 2004/073641	9/2/2004	WO			*	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	KIKUCHI et al., "Dendritic Cells Modified to Express CD40 Ligand Elicit Therapeutic Immunity Against Preexisting Murine Tumors", July 2000, pp. 91-99.
	KONTANI et al., "Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model", 2002, Cancer Gene Therapy, 8 pages.

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

\* English language abstract provided for the Examiner's convenience

RJP/blg

Y&amp;T September 6, 2007